Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial

@inproceedings{Rossetti2017SwitchTM,
  title={Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial},
  author={Barbara Rossetti and Roberta Gagliardini and Genny Meini and Gaetana Sterrantino and Vincenzo Colangeli and Maria Carla Re and Alessandra Latini and Manuela Colafigli and Francesca Vignale and Stefano Rusconi and Valeria Micheli and Antonio Di Biagio and Giancarlo Orofino and Valeria Ghisetti and Alessandra Fantauzzi and Vincenzo Vullo and Pierfrancesco Grima and Daniela Francisci and Claudio Maria Mastroianni and Andrea Antinori and Michele Trezzi and Lucia Lisi and Pierluigi Navarra and Benedetta Canovari and Antonella d'Arminio Monforte and Silvia Lamonica and Alessandro D'Avino and Maurizio Zazzi and Simona di Giambenedetto and Andrea De Luca},
  booktitle={PloS one},
  year={2017}
}
OBJECTIVES Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48. METHODS Patients on 3-drug ART with stable HIV-1 RNA <50 copies/mL and CCR5-tropic virus were randomized 1:1 to maraviroc with darunavir/ritonavir qd (study arm) or continue current ART (continuation arm). RESULTS In June 2015, 115 patients were evaluable for the primary outcome (56 study, 59 continuation arm). The study was discontinued due to… CONTINUE READING